|
SEOUL, South Korea, Jan. 21, 2026 /PRNewswire/ -- FutureMain, a South Korea–based industrial AI and asset transformation (AX) company specializing in predictive maintenance, announced that it is actively conducting phased field validation research on AI-powered self-diagnostic technologies for high-failure-rate industrial equipment as part of a government-funded national R&D program led by the Korea Evaluation Institute of Industrial Technology (KEIT).
The project, titled "Development and Demonstration of Federated Learning–Based On-Device AI Self-Diagnostics for High-Failure-Rate Equipment," aims to reduce reliance on centralized servers by enabling real-time, on-site AI diagnostics directly at industrial facilities. The long-term program runs from 2024 through 2027 and focuses on deploying scalable, privacy-preserving AI technologies suitable for real-world manufacturing environments.
Through this initiative, FutureMain is validating AI-based diagnostic technologies across more than 30 major industrial assets, prioritizing equipment with high failure frequencies and complex maintenance requirements. The core objective is to verify a system architecture capable of analyzing equipment conditions and detecting early-stage anomalies using operational data in live industrial settings.
A key differentiator of the project is its on-device AI diagnostic framework, which processes data locally at the equipment level rather than relying on continuous cloud connectivity. This approach enables reliable deployment even in industrial environments with limited or unstable communication infrastructure, expanding applicability across diverse global manufacturing sites.
As the lead organization of the consortium, FutureMain is responsible for the collection, integration, and convergence analysis of equipment and process data, as well as the development of automated fault diagnosis, asset condition assessment technologies, and federated learning–based data privacy and security frameworks.
Consortium partners include the Advanced Institute of Convergence Technology (AICT), which leads the development of federated learning–based remaining useful life (RUL) prediction algorithms; Sibery Solutions, which is developing the SmartMRO-Hub platform to optimize maintenance operations based on diagnostic outcomes; and MathAI, which is responsible for multilingual equipment voice recognition and sLLM-based conversational HMI technologies.
Rather than pursuing short-term outcomes, the project is designed to progressively advance AI-driven equipment diagnostics toward practical, industrial-grade deployment. FutureMain plans to continuously evaluate both technical maturity and field applicability throughout the project lifecycle, building a foundation to establish new benchmarks in intelligent asset management.
"In an environment where opportunities for domestic AI companies and research institutions to collaborate on high-level industrial R&D are limited, this project is particularly meaningful," said Shinhye Lee, Director at FutureMain. "It demonstrates that advanced equipment and process optimization can be achieved using homegrown technologies, while also driving the development of a differentiated, integrated AX solution that combines MRO and LLM technologies."
She added, "Our ultimate goal is to enable optimal management of high-failure-rate equipment and move toward the realization of zero-downtime factories."
The developed technologies were showcased at CES 2026, where FutureMain exhibited at Eureka Park and introduced its AI-based equipment diagnostics to global industry stakeholders. During the event, the company engaged in technical exchanges with international partners and discussed potential applications across global industrial sites.
As part of its global expansion efforts, FutureMain signed memorandums of understanding (MOUs) with Belgium-based Soundnodes and Türkiye-based airgemba to support entry into the European market, along with two additional cooperation agreements, bringing the total to four new MOUs. Approximately USD 4 million in export consultations were conducted during the exhibition, further validating the company's global business potential.
Building on the technical validation and research experience accumulated through this project, FutureMain also exhibited in ADIPEC 2025, expanding collaboration discussions across the Middle East and other global industrial markets. The company expects that the technological credibility and real-world validation secured through this long-term initiative will serve as a critical foundation for future global expansion.
SEOUL, South Korea, Jan. 21, 2026 /PRNewswire/ -- FutureMain, a South Korea–based industrial AI and asset transformation (AX) company specializing in predictive maintenance, announced that it is actively conducting phased field validation research on AI-powered self-diagnostic technologies for high-failure-rate industrial equipment as part of a government-funded national R&D program led by the Korea Evaluation Institute of Industrial Technology (KEIT).
The project, titled "Development and Demonstration of Federated Learning–Based On-Device AI Self-Diagnostics for High-Failure-Rate Equipment," aims to reduce reliance on centralized servers by enabling real-time, on-site AI diagnostics directly at industrial facilities. The long-term program runs from 2024 through 2027 and focuses on deploying scalable, privacy-preserving AI technologies suitable for real-world manufacturing environments.
Through this initiative, FutureMain is validating AI-based diagnostic technologies across more than 30 major industrial assets, prioritizing equipment with high failure frequencies and complex maintenance requirements. The core objective is to verify a system architecture capable of analyzing equipment conditions and detecting early-stage anomalies using operational data in live industrial settings.
A key differentiator of the project is its on-device AI diagnostic framework, which processes data locally at the equipment level rather than relying on continuous cloud connectivity. This approach enables reliable deployment even in industrial environments with limited or unstable communication infrastructure, expanding applicability across diverse global manufacturing sites.
As the lead organization of the consortium, FutureMain is responsible for the collection, integration, and convergence analysis of equipment and process data, as well as the development of automated fault diagnosis, asset condition assessment technologies, and federated learning–based data privacy and security frameworks.
Consortium partners include the Advanced Institute of Convergence Technology (AICT), which leads the development of federated learning–based remaining useful life (RUL) prediction algorithms; Sibery Solutions, which is developing the SmartMRO-Hub platform to optimize maintenance operations based on diagnostic outcomes; and MathAI, which is responsible for multilingual equipment voice recognition and sLLM-based conversational HMI technologies.
Rather than pursuing short-term outcomes, the project is designed to progressively advance AI-driven equipment diagnostics toward practical, industrial-grade deployment. FutureMain plans to continuously evaluate both technical maturity and field applicability throughout the project lifecycle, building a foundation to establish new benchmarks in intelligent asset management.
"In an environment where opportunities for domestic AI companies and research institutions to collaborate on high-level industrial R&D are limited, this project is particularly meaningful," said Shinhye Lee, Director at FutureMain. "It demonstrates that advanced equipment and process optimization can be achieved using homegrown technologies, while also driving the development of a differentiated, integrated AX solution that combines MRO and LLM technologies."
She added, "Our ultimate goal is to enable optimal management of high-failure-rate equipment and move toward the realization of zero-downtime factories."
The developed technologies were showcased at CES 2026, where FutureMain exhibited at Eureka Park and introduced its AI-based equipment diagnostics to global industry stakeholders. During the event, the company engaged in technical exchanges with international partners and discussed potential applications across global industrial sites.
As part of its global expansion efforts, FutureMain signed memorandums of understanding (MOUs) with Belgium-based Soundnodes and Türkiye-based airgemba to support entry into the European market, along with two additional cooperation agreements, bringing the total to four new MOUs. Approximately USD 4 million in export consultations were conducted during the exhibition, further validating the company's global business potential.
Building on the technical validation and research experience accumulated through this project, FutureMain also exhibited in ADIPEC 2025, expanding collaboration discussions across the Middle East and other global industrial markets. The company expects that the technological credibility and real-world validation secured through this long-term initiative will serve as a critical foundation for future global expansion.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
FutureMain Advances AI-Based On-Device Diagnostics for High-Failure-Rate Equipment Through Government-Led R&D Program, Validating Global Industrial Applicability
|
- Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicines
TORONTO, Jan. 21, 2026 /PRNewswire/ -- Daiichi Sankyo (TSE: 4568) has further established its presence in Canada with the official opening of its permanent headquarters in Toronto, including additional operational and research and development investment, underscoring the strategic importance of Canada in the growth of Daiichi Sankyo as a global leader in oncology.
"Establishing a permanent headquarters in Toronto represents a significant milestone in our global expansion and reflects the strong commitment of Daiichi Sankyo to patients and partners in Canada," said Masahiro Kato, Managing Director, Europe and Canada, Daiichi Sankyo. "Canada is home to a vibrant healthcare and life sciences ecosystem where we see immense potential for continued growth through scientific innovation and collaboration, solidifying Canada's role as a global contributor to improve standards of care."
"Our government is protecting Ontario by cutting taxes and red tape, saving businesses $12 billion a year so that we can drive economic growth and welcome investments just like this one. Daiichi Sankyo's investment will help create good-paying jobs, strengthen our economy and reinforce Ontario's position as a world-class hub for innovation and health research. I want to thank Daiichi Sankyo for their confidence in Ontario's incredible workers," said Ontario Premier Doug Ford.
"This opening marks the beginning of an exciting new chapter for Daiichi Sankyo in Canada where we are further establishing our presence in Toronto as we continue to expand access to our oncology portfolio," added Fatih Yedikardeş, Country Manager, Canada, Daiichi Sankyo. "This expansion means improving access to our medicines and strengthening our partnerships with healthcare professionals and the broader life sciences community in Canada."
"As the largest life sciences jurisdiction in Canada, Ontario is a prime location for domestic and international pharmaceutical companies to establish their headquarters and advance their research from lab to market. We congratulate Daiichi Sankyo on the opening of their new Canadian headquarters here in Toronto and look forward to seeing the next chapter of their biomedical innovation that will leverage Ontario's highly skilled workforce and R&D capabilities," said Vic Fedeli, Ontario Minister of Economic Development, Job Creation and Trade.
Over the past two years, Daiichi Sankyo has supported 18 oncology clinical trials across 43 sites in Canada, working with top cancer centres such as Princess Margaret Cancer Centre, CHUM, BC Cancer, McGill University Health Centre and The Ottawa Hospital.
"By establishing their Canadian headquarters in Toronto, Daiichi Sankyo is affirming Ontario's place as a hub of health innovation. This investment in Ontario will advance access to innovative cancer medicines for Ontario families, building on our government's actions to date to connect patients to cutting-edge, life-saving cancer drugs faster," added Sylvia Jones, Ontario Deputy Premier and Minister of Health.
To mark the occasion, Daiichi Sankyo hosted an office opening celebration featuring a traditional Kagami Biraki (sake barrel breaking) ceremony, symbolizing new beginnings, harmony and prosperity, followed by a Japanese taiko drumming performance honouring the company's cultural heritage. The event brought together company leadership, government representatives and partners to commemorate the milestone.
The official opening of the Daiichi Sankyo headquarters in Canada cements its position as a dedicated partner in the Canadian healthcare system. Driven by strategic investment and a rapidly expanding team, Daiichi Sankyo is focused on accelerating access to its oncology pipeline and building a healthier future for Canadians.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.
Media Contact: Sarah Douglas, Media_ca@daiichisankyo.com
- Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicines
TORONTO, Jan. 21, 2026 /PRNewswire/ -- Daiichi Sankyo (TSE: 4568) has further established its presence in Canada with the official opening of its permanent headquarters in Toronto, including additional operational and research and development investment, underscoring the strategic importance of Canada in the growth of Daiichi Sankyo as a global leader in oncology.
"Establishing a permanent headquarters in Toronto represents a significant milestone in our global expansion and reflects the strong commitment of Daiichi Sankyo to patients and partners in Canada," said Masahiro Kato, Managing Director, Europe and Canada, Daiichi Sankyo. "Canada is home to a vibrant healthcare and life sciences ecosystem where we see immense potential for continued growth through scientific innovation and collaboration, solidifying Canada's role as a global contributor to improve standards of care."
"Our government is protecting Ontario by cutting taxes and red tape, saving businesses $12 billion a year so that we can drive economic growth and welcome investments just like this one. Daiichi Sankyo's investment will help create good-paying jobs, strengthen our economy and reinforce Ontario's position as a world-class hub for innovation and health research. I want to thank Daiichi Sankyo for their confidence in Ontario's incredible workers," said Ontario Premier Doug Ford.
"This opening marks the beginning of an exciting new chapter for Daiichi Sankyo in Canada where we are further establishing our presence in Toronto as we continue to expand access to our oncology portfolio," added Fatih Yedikardeş, Country Manager, Canada, Daiichi Sankyo. "This expansion means improving access to our medicines and strengthening our partnerships with healthcare professionals and the broader life sciences community in Canada."
"As the largest life sciences jurisdiction in Canada, Ontario is a prime location for domestic and international pharmaceutical companies to establish their headquarters and advance their research from lab to market. We congratulate Daiichi Sankyo on the opening of their new Canadian headquarters here in Toronto and look forward to seeing the next chapter of their biomedical innovation that will leverage Ontario's highly skilled workforce and R&D capabilities," said Vic Fedeli, Ontario Minister of Economic Development, Job Creation and Trade.
Over the past two years, Daiichi Sankyo has supported 18 oncology clinical trials across 43 sites in Canada, working with top cancer centres such as Princess Margaret Cancer Centre, CHUM, BC Cancer, McGill University Health Centre and The Ottawa Hospital.
"By establishing their Canadian headquarters in Toronto, Daiichi Sankyo is affirming Ontario's place as a hub of health innovation. This investment in Ontario will advance access to innovative cancer medicines for Ontario families, building on our government's actions to date to connect patients to cutting-edge, life-saving cancer drugs faster," added Sylvia Jones, Ontario Deputy Premier and Minister of Health.
To mark the occasion, Daiichi Sankyo hosted an office opening celebration featuring a traditional Kagami Biraki (sake barrel breaking) ceremony, symbolizing new beginnings, harmony and prosperity, followed by a Japanese taiko drumming performance honouring the company's cultural heritage. The event brought together company leadership, government representatives and partners to commemorate the milestone.
The official opening of the Daiichi Sankyo headquarters in Canada cements its position as a dedicated partner in the Canadian healthcare system. Driven by strategic investment and a rapidly expanding team, Daiichi Sankyo is focused on accelerating access to its oncology pipeline and building a healthier future for Canadians.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.
Media Contact: Sarah Douglas, Media_ca@daiichisankyo.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
